• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Omnicare offers $457 million to buy PharMercia

Omnicare offers $457 million to buy PharMercia

August 24, 2011
CenterWatch Staff

Omnicare went public with a $457 million offer for pharmacy management services company PharMerica, sending shares of both companies surging.

Omnicare dispenses drugs for nursing homes and other long-term care centers. Omnicare CEO John Figueroa said in a letter to the PharMerica board that its CEO, Gregory Weishar, approached him about exploring a combination of the companies back in April, and Figueroa expressed interest to Weishar several times. PharMerica's CEO was not named in the letter.

Figueroa wrote that PharMerica then refused to start negotiations. Counting PharMerica's debt, Omnicare values the deal at about $716 million.

Figueroa said a combination of the companies would save money and broaden services, among other benefits. The CEO also said in the letter that Omnicare's "strong preference" is to negotiate a mutually acceptable deal with PharMerica. The company's proposal is not subject to financing contingencies.

"However, if you continue to refuse to engage in meaningful negotiations, we are prepared to submit our proposal directly to your stockholders," he wrote.

Credit Suisse analyst Glen Santangelo said he expects either an increased bid from Omnicare, or an offer from a private equity firm that is interested in PharMerica.

"We believe PharMerica may be interested in finding a financial buyer which would keep the company intact and allow management to retain their current positions," he wrote.

Both companies stand to benefit as blockbuster drugs like Lipitor, Plavix and others lose patent protection over the next few years. That will allow cheaper generic versions to enter the market, and it means bigger profit margins for Omnicare and PharMerica.

PharMerica accused Omnicare of "self-serving tactics" in taking the offer public. The Louisville, Ky., company said it has rejected Omnicare's offers because they undervalue the company and are not in the best interest of PharMerica's shareholders. PharMerica added that it is open to discussing a transaction, but that a deal with Omnicare could be disruptive to its customers and employees, and Omnicare is not willing to assume the risks involved in completing the proposed deal.

"Antitrust clearance ... is likely to be difficult to achieve and involve lengthy administrative and court proceedings," PharMerica said. Omnicare and PharMerica are the two largest institutional pharmacy companies in the U.S., and according to Santangelo, they control a combined 60% of the market. Santangelo said the Federal Trade Commission would probably require the companies to divest some businesses before it approved any sale.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing